Navigation Links
Ohr Pharmaceutical Announces $5 Million Financing from Exercise of Warrants
Date:4/22/2013

NEW YORK, April 22, 2013 /PRNewswire/ -- Ohr Pharmaceutical Inc. (OTCQB: OHRP), a pharmaceutical company focused on the development of novel therapeutics for unmet medical needs, today announced that Ohr raised approximately $5.05 million dollars from institutional and accredited shareholders through the exercise of Series B Warrants.  The Company intends to use the net proceeds from this offering to complete its Phase II Squalamine eye drop clinical trial for the wet form of age-related macular degeneration, further the clinical development of Squalamine eye drops for the treatment of other neovascular ophthalmic disorders, fund continued development of other pipeline molecules, and for general corporate purposes.

"The Company's ability to raise significant capital on favorable terms and provide itself with a cash runway into 2015 is a confirmation of the continued progress on the Company's clinical development programs," said Ira Greenstein , Chairman of the Board of Directors. "The additional capital will allow us to continue to execute on the Company's strategy and increases shareholder equity, one of the requirements for our proposed uplisting to Nasdaq."

"We would like to thank our shareholders for their continued support," said Dr. Irach B. Taraporewala, CEO of Ohr Pharmaceutical. "I am pleased to report that we anticipate completing 50% enrollment in the Phase II Squalamine eye drop trial midyear and look forward to continuing to update shareholders on the progress of our clinical trial and business initiatives."   

About the Warrant Exercise

On April 5, 2013, the Company gave notice to Series B Warrant holders that the Company was opting to accelerate the expiration date of the Series B Warrants to April 18, 2013. Additionally, as an incentive to encourage exercise of the Series B Warrants, the Company offered to those Series B Warrant holders
'/>"/>

SOURCE Ohr Pharmaceutical Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. DSM announces June opening of new cGMP biopharmaceutical manufacturing operation in Brisbane, Australia
2. Shimadzu's New DSC-60 Plus Series Differential Scanning Calorimeters Offer High-Sensitivity Analysis in Polymer, Food and Pharmaceutical Applications
3. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
4. PharmaDirections Celebrates 10 Years of Success for Their Virtual Biotech and Pharmaceutical Clients
5. North American Nuclear Medicine / Radiopharmaceutical Market Worth $5.55 Billion by 2017
6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
8. Executives from Johnson & Johnson, GlaxoSmithKline and California State Board of Pharmacy discuss pharmaceutical packaging challenges at Pharmapack North America 2013
9. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
10. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
11. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... 2015 Prostate cancer is the second ... men. One in seven men will be diagnosed ... are diagnosed annually. That said, not every diagnosis ... new technique, MRI Fusion Biopsy, to more accurately ... only the affected areas and monitoring areas ...
(Date:9/1/2015)... ... 01, 2015 , ... In her thought provoking debut novel ‘ Ebola Vaccine ... future faced with an Ebola pandemic that is on the cusp of wiping out ... the world of counterterrorism, and who continues to appear in this series of books ...
(Date:9/1/2015)... ... 2015 , ... VetStem Biopharma announces new Clinical Research program ... can be caused by injuries and abnormalities of the cervical spine. Arthritic cervical ... the spinal cord itself. This can manifest itself as any or all of ...
(Date:9/1/2015)... ... September 01, 2015 , ... Leading ... neuro and pain management space join prominent academics and key investors for Neuro ... Harvard Medical School in Boston. , Neuro Advance Boston focuses on the ...
Breaking Biology Technology:September Is Prostate Cancer Awareness Month 2September Is Prostate Cancer Awareness Month 3September Is Prostate Cancer Awareness Month 4Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 2Alexi Venice’s Debut Novel Takes on the Human Testing of a Vaccine for Ebola and Revenge by an Anti-Big Pharma Terrorist Group in ‘Ebola Vaccine Wars' 3VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 2VetStem Biopharma Announces New Clinical Research Program for Equine Cervical Facet Joint Disease 3Neuro Advance Boston Brings Together Leading Neuroscience Experts on October 14 at Harvard Medical School 2
... 6, 2011 Van Andel Education Institute (VAEI) has ... to cooperatively recruit students interested in research training in ... genetic biology of human disease.    Under ... will work together to recruit qualified students at historically ...
...  Research Corporation for Science Advancement ( www.rescorp.org ), ... wholly to science, and the second-oldest overall (after ... its Honorary Centennial Observance Committee. The Committee, which ... 2012, is comprised of some of the most ...
... Inc. (Nasdaq: ECTE ), a company developing ... continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep ... from its clinical study of its Symphony tCGM System ... Data from the study confirm that Symphony successfully monitors ...
Cached Biology Technology:Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers 2Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... diverse potential applications include the development of ... coatings for medical implants, coatings for semiconductors, ... materials, microelectronics and responsive nanomaterials, and surface-sensitive ... The patented technology stems from the discovery ...
... have contended for millennia that burning incense is good ... is good for our brains too. In a new ... ), an international team of scientists, including researchers from ... describe how burning frankincense (resin from the Boswellia plant) ...
... First identified in 1899, y-larvae have been one of ... one has ever found an adult of these puzzling ... leading generations of marine zoologists to wonder just what ... in BioMed Centrals open access journal, BMC Biology, reports ...
Cached Biology News:Scripps Research Institute awarded patent for remarkable chemical technology 2Scripps Research Institute awarded patent for remarkable chemical technology 3Scripps Research Institute awarded patent for remarkable chemical technology 4Incense is psychoactive: Scientists identify the biology behind the ceremony 2Clue to mystery crustacean in parasite form 2
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
Biology Products: